Showing results (61-70 of 127) with videos related to

Sort By:
Pageof 13
Plos One|March 14, 2024
Antibody desolvation with sodium chloride and acetonitrile generates bioactive protein nanoparticlesLevi Collin Nelemans, Vinicio Alejandro Melo, Matej Buzgo, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 5, 2014
Dual-Modality Image-Guided Surgery of Prostate Cancer with a Radiolabeled Fluorescent Anti-PSMA Monoclonal AntibodySusanne Lütje, Mark Rijpkema, Gerben M Franssen, et al.
Oncoimmunology|May 14, 2023
Novel Fab-peptide-HLA-I fusion proteins for redirecting pre-existing anti-CMV T cell immunity to selective eliminate carcinoma cellsIsabel Britsch, Anne P van Wijngaarden, Xiurong Ke, et al.
Cancers|July 29, 2023
A Novel Bispecific Antibody for EpCAM-Directed Inhibition of the CD73/Adenosine Immune Checkpoint in Ovarian CancerEmily Maria Ploeg, Isabel Britsch, Anne Paulien van Wijngaarden, et al.
Current Pharmaceutical Design|February 26, 2013
SNAP-tag based agents for preclinical in vitro imaging in malignant diseasesManal Amoury, Tobias Blume, Hannes Brehm, et al.
ACS Chemical Biology|February 6, 2024
Visible Light Control over the Cytolytic Activity of a Toxic Pore-Forming ProteinJana Volarić, Nieck J van der Heide, Natalie L Mutter, et al.
Cancer Immunology, Immunotherapy : CII|November 20, 2021
Endoplasmic reticulum stress-induced release and binding of calreticulin from human ovarian cancer cellsTrefa M Abdullah, Jacqueline Whatmore, Edwin Bremer, et al.
Contrast Media & Molecular Imaging|April 26, 2014
Targeting human prostate cancer with 111In-labeled D2B IgG, F(ab')2 and Fab fragments in nude mice with PSMA-expressing xenograftsSusanne Lütje, Catharina M van Rij, Gerben M Franssen, et al.
Journal of Neuro-Oncology|April 7, 2006
The efficacy of alginate encapsulated CHO-K1 single chain-TRAIL producer cells in the treatment of brain tumorsJos M A Kuijlen, Bart J de Haan, Wijnand Helfrich, et al.
Oncotarget|September 22, 2016
CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapyFenne L Komdeur, Maartje C A Wouters, Hagma H Workel, et al.
Pageof 13